Onconova Therapeutics, Inc. (NASDAQ:ONTX) management will conduct a conference call for 12th August 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.onconova.com
Earnings Expectation
Onconova Therapeutics, Inc. is reporting second quarter financial results on Wednesday 12th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ONTX is expected to report 2Q20 loss of $ 0.03 per share from revenue of $ 0.17 million.
For the full year, analysts anticipate top line of $ 3.09 million, while looking forward to loss of $ 0.12 per share bottom line.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.
